Doug Biehn, President and CEO of Octave Biosciences, talks about the difference that a biomarker test can make in the management of multiple sclerosis.
Comments
0
Be the first to comment
Sign up now and become a member of the On Target Podcast community!
Comments
0Be the first to comment
Sign up now and become a member of the On Target Podcast community!